Careers Media center Contacts

New drug from Arterium is on the List of drugs for COVID-19 patients’ medical care

New drug from Arterium is on the List of drugs for COVID-19 patients’ medical care

1 July 2020 | News

Ringera solution is used to reduce blood volume, dehydration due to prolonged vomiting, diarrhoea and other conditions that accompany electrolyte imbalance. Such imbalance can lead to lower blood pressure, fluid retention, kidney problems and other complications.

Salts that make up the drug are sodium chloride, potassium chloride and calcium chloride dihydrate. These allow for the restoration of the electrolyte balance due to the more "physiological" composition of ions, which is closer to the ionic composition of blood plasma than isotonic sodium chloride solution.

The Resolution of the Cabinet of Ministers of Ukraine from March 20, 2020 № 225 includes Ringera solution in the List of medicines for treating patients with COVID-19.

"The corporation produces 25 drugs out of 96 in the list of medicines for the care of patients with COVID-19, approved by the Resolution of the Cabinet of Ministers of Ukraine on March 20, 2020 № 225, and this is our contribution to the fight against the epidemic in Ukraine," commented Serhiy Sur, head of interaction with regulatory authorities.

The company plans to transfer the first batches of the manufactured Ringera solution to medical institutions in Ukraine.

Arterium currently has a wide range of antibiotics for the treatment of complications caused by the coronavirus in its portfolio. Since the start of the pandemic the company has been working to ensure timely access to drugs prescribed for the treatment of patients with this viral infection. In particular, the production of the antimicrobial drugs Linezolidine and Mepenam, which are used for complications caused by coronavirus infection, has increased several times. The company closely monitors the situation with the development and testing of drugs both for the treatment of complications arising from coronavirus infection and for the fight against the virus itself. The promising Arterium portfolio already includes a product that has antiviral properties and has already shown positive results in the treatment of patients with coronavirus.

 

Media gallery
PRESS KIT

Here you can find general information about the company intended for journalists and other stakeholders

MEDIA CONTACTS

For all media-related enquiries,
please contact us
e-mail: pr@arterium.ua
mob.: +38050 446 71 20, +38095 278 92 80